Bayer is accelerating efforts to conclude its global settlement with plaintiffs alleging cancer links to its Roundup herbicide, imposing a new deadline on claimants to accept terms.
The move follows a decisive legal victory for the company last week, when the US Supreme Court ruled in Bayer’s favor, effectively ending the possibility of further appeals in the core litigation.
The German industrial group is using the momentum from the high-court decision to pressure remaining claimants into finalizing the agreement.
According to Handelsblatt, the Supreme Court win has galvanized all parties involved in the out-of-court negotiations, with Bayer now seeking to close the chapter on what has been one of the most costly legal battles in corporate history.
This development marks a significant shift in the risk profile for Bayer, which has faced billions of dollars in liabilities and reputational damage from the glyphosate lawsuits.
The Supreme Court’s ruling, which upheld a lower court’s dismissal of a key case, removed a major source of uncertainty for investors who have long viewed the litigation as a drag on the company’s valuation.